A comparative study of two PODXL antibodies in 840 colorectal cancer patients

BACKGROUND: Podocalyxin (PODXL) is a transmembrane sialomucin, whose aberrant expression and/or allelic variation associates with poor prognosis and unfavourable clinicopathological characteristics in different cancers. Membranous expression of PODXL has been suggested to be an independent marker of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaprio, Tuomas, Hagström, Jaana, Fermér, Christian, Mustonen, Harri, Böckelman, Camilla, Nilsson, Olle, Haglund, Caj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107962/
https://www.ncbi.nlm.nih.gov/pubmed/25004935
http://dx.doi.org/10.1186/1471-2407-14-494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107962/
https://www.ncbi.nlm.nih.gov/pubmed/25004935
http://dx.doi.org/10.1186/1471-2407-14-494

Ejemplares similares